Cognitive Disorders and Oxidative Stress Status Attenuated by Chrysophyllum Perpulchrum Extract in Alzheimer- like Rat Model of Intracerebroventricular Aβ1-40 injection

Abstract

Chrysophyllum perpulchrum is an endemic medicinal plant used in ivorian tranditional pharmacopeiaeas antipyretic to heal malaria fever. Since three flavonoid compounds have been isolated, catechin and two procyanid in dimers, we are proposed to testthe neuroprotective effectiveness effects using a rat model of Alzheimer Disease (AD). Adult Wistar rats were used as model.Sham-operated rats as controlwere injected by intracerebroventricular route (i.c.v) with1% ammonia(Group1), Aβ rats were microinjected with 10µg/side (i.c.v route, (Group 2)).From 14th day post-surgery required for neuro inflammation and oxidative stress induction,some Aβ-injected rats were daily treated with the extract (300 mg/kg bw, oral route, (Group 3)) for 21 days,sham-operated rats were treated only with plant extract (300 mg/kg bw, oral route, (Group 4)). Rats were then submitted to memory tests with Y maze, object recognition test and Morris water maze. Some oxidative stress markershave been assessed.AD-like rats exhibited significant recognition memory as well as learning and spatial memory deficits.The treatment of AD like-rats with methanolic extract of Chrysophyllum perpulchrum alleviated cognitive disorders by improving the memory recognition index and spatial learning strategy to find the hidden platform. Furthermore,Chrysophyllum perpulchrum extract prevented significantly Aβ-induced lipid proxidation through a decrease of malondialdehyde (MDA) level in the hippocampus and the prefrontal cortex, and also helped to increase the non protein-thiol (NP-SH) antioxidant level.These findings suggest the neuroprotective actions of Chrysophyllum perpulchrum extract on AD-like rats. However,further pharmacological studies are needed to test ability of isolated compounds from Chrysophyllum perpulchrum to counteract full Aβ physiopathology mechanisms before promising to be a drug candidate for AD treatment.